Marie Kersten

20002020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Comment/Letter to the editor
2018

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K. & Kersten, M. J., 2018, In : Blood cancer journal. 8, 2, 16.

Research output: Contribution to journalComment/Letter to the editorAcademic

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma

Schrader, A. M. R., Jansen, P. M., Willemze, R., Vermeer, M. H., Cleton-Jansen, A-M., Somers, S. F., Veelken, H., van Eijk, R., Kraan, W., Kersten, M. J., van den Brand, M., Stevens, W. B. C., de Jong, D., Hamid, M. A., Tanis, B. C., Posthuma, E. F. M., Nijland, M., Diepstra, A., Pals, S. T., Cleven, A. H. G. & 1 others, Vermaat, J. S. P., 2018, In : Blood. 131, 18, p. 2086-2089

Research output: Contribution to journalComment/Letter to the editorAcademic